Carbary-Ganz Jordan L, Barton Jennifer K, Utzinger Urs
J Biomed Opt. 2014 Aug;19(8):086003. doi: 10.1117/1.JBO.19.8.086003.
We successfully labeled colorectal cancer in vivo using quantum dots targeted to vascular endothelial growth factor receptor 2 (VEGFR2). Quantum dots with emission centered at 655 nm were bioconjugated to anti-VEGFR2 antibodies through streptavidin/biotin linking. The resulting QD655-VEGFR2 contrast agent was applied in vivo to the colon of azoxymethane (AOM) treated mice via lavage and allowed to incubate. The colons were then excised, cut longitudinally, opened to expose the lumen, and imaged en face using a fluorescence stereoscope. The QD655-VEGFR2 contrast agent produced a significant increase in contrast between diseased and undiseased tissues, allowing for fluorescence-based visualization of the diseased areas of the colon. Specificity was assessed by observing insignificant contrast increase when labeling colons of AOM-treated mice with quantum dots bioconjugated to isotype control antibodies, and by labeling the colons of saline-treated control mice. This contrast agent has a great potential for in vivo imaging of the colon through endoscopy.
我们利用靶向血管内皮生长因子受体2（VEGFR2）的量子点成功地在体内标记了结肠直肠癌。发射中心波长为655 nm的量子点通过链霉亲和素/生物素连接与抗VEGFR2抗体进行生物共轭。将所得的QD655 - VEGFR2造影剂通过灌洗法应用于经氧化偶氮甲烷（AOM）处理的小鼠结肠，并使其孵育。然后切除结肠，纵向切开，打开以暴露肠腔，并使用荧光立体显微镜进行正面成像。QD655 - VEGFR2造影剂使病变组织与未病变组织之间的对比度显著增加，从而能够基于荧光可视化结肠的病变区域。通过观察用与同型对照抗体生物共轭的量子点标记AOM处理小鼠的结肠时对比度增加不显著，以及标记生理盐水处理的对照小鼠的结肠来评估特异性。这种造影剂在通过内窥镜进行结肠体内成像方面具有巨大潜力。
